TARS Stock Price, Tarsus Pharmaceuticals Quote, Chart

Market Summary

USD38.45+1.45

Market Closed

3.92%

TARS Alerts

Big jump in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

TARS Stock Price

View Fullscreen

TARS RSI Chart

TARS Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-9.8

Price/Sales (Trailing)

32.24

EV/EBITDA

-9.79

Price/Free Cashflow

-10.79

TARS Price/Sales (Trailing)

TARS Profitability

EBT Margin

-301.58%

Return on Equity

-53.85%

Return on Assets

-42.43%

Free Cashflow Yield

-9.27%

TARS Fundamentals

TARS Revenue

Revenue (TTM)

45.1M

Rev. Growth (Yr)

1.0K%

Rev. Growth (Qtr)

111.18%

TARS Earnings

Earnings (TTM)

-148.2M

Earnings Growth (Yr)

-52.57%

Earnings Growth (Qtr)

14.73%

Breaking Down TARS Revenue

Last 7 days

3.8%

Last 30 days

6.3%

Last 90 days

29.7%

Trailing 12 Months

133.2%

How does TARS drawdown profile look like?

TARS Financial Health

Current Ratio

8.01

Debt/Equity

0.11

Debt/Cashflow

-4.45

TARS Investor Care

Shares Dilution (1Y)

40.96%

Diluted EPS (TTM)

-4.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	45.1M	0	0	0
2023	27.8M	0	14.4M	27.4M
2022	49.2M	41.4M	33.6M	25.8M
2021	0	0	0	57.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tarsus Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	wahl bryan	sold	-135,742	30.6	-4,436	general counsel
Mar 18, 2024	azamian bobak r.	sold	-318,699	30.6	-10,415	president/ceo and board chair
Mar 18, 2024	mottiwala aziz	sold	-145,840	30.6	-4,766	chief commercial officer
Mar 18, 2024	neervannan seshadri	sold	-149,297	30.6	-4,879	chief operating officer
Mar 18, 2024	whitfield dianne c.	sold	-132,008	30.6	-4,314	chief human resources officer
Mar 15, 2024	wahl bryan	acquired	-	-	12,038	general counsel
Mar 15, 2024	azamian bobak r.	acquired	-	-	28,274	president/ceo and board chair
Mar 15, 2024	mottiwala aziz	acquired	-	-	12,938	chief commercial officer
Mar 15, 2024	whitfield dianne c.	acquired	-	-	11,711	chief human resources officer
Mar 15, 2024	neervannan seshadri	acquired	-	-	13,245	chief operating officer

Which funds bought or sold TARS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	WELLS FARGO & COMPANY/MN	added	20.39	231,894	431,620	-%
May 10, 2024	CITIGROUP INC	added	17.88	270,740	513,335	-%
May 10, 2024	Jackson Creek Investment Advisors LLC	new	-	1,075,000	1,075,000	0.38%
May 10, 2024	OSAIC HOLDINGS, INC.	added	23.33	4,425	8,070	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	reduced	-1.23	6,731,890	15,442,600	-%
May 10, 2024	CREDIT SUISSE AG/	added	1.63	450,936	997,990	-%
May 10, 2024	Sargent Investment Group, LLC	reduced	-25.88	74,405	299,524	0.07%
May 10, 2024	JPMORGAN CHASE & CO	added	108	1,421,080	1,938,870	-%
May 10, 2024	Covestor Ltd	new	-	-	-	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	3,460	6,370	6,471	-%

Are Funds Buying or Selling TARS?

Are funds buying TARS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TARS

No. of Funds

Unveiling Tarsus Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	cormorant asset management, lp	4.83%	1,600,000	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.5%	3,152,341	SC 13G/A
Feb 14, 2024	tang capital partners lp	6.7%	2,204,797	SC 13G/A
Feb 13, 2024	vivo capital ix, llc	2.7%	894,826	SC 13G/A
Feb 09, 2024	morgan stanley	5.9%	1,943,705	SC 13G
Feb 02, 2024	cowen financial products llc	5.77%	1,911,399	SC 13G/A
Feb 02, 2024	timessquare capital management, llc	0%	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.6%	2,515,124	SC 13G
Jan 22, 2024	paradigm biocapital advisors lp	5.8%	1,927,506	SC 13G
May 05, 2023	cowen financial products llc	5.22%	1,398,983	SC 13G

Recent SEC filings of Tarsus Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 23, 2024	8-K	Current Report
Apr 11, 2024	144	Notice of Insider Sale Intent
Mar 28, 2024	144	Notice of Insider Sale Intent
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to Tarsus Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Tarsus Pharmaceuticals Inc News

Latest updates

Tarsus Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)												(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	111.2%	27,614,000	13,076,000	1,871,000	2,500,000	10,000,000	-	15,277,000	7,807,500	338,000	1,240,000	22,017,000	33,432,000
Costs and Expenses	-	65,298,000	-	42,806,000	27,452,000	-	22,906,000	20,501,000	20,060,000	-	16,945,000	-	-
Operating Expenses	-	-	-	-	-	-	-	20,501,000	20,060,000	14,786,000	16,945,000	14,735,000	22,718,000
S&GA Expenses	-100.0%	-	43,005,000	30,324,000	15,096,000	14,633,000	11,994,000	10,376,000	7,946,000	6,772,000	6,671,000	6,794,000	5,160,000
R&D Expenses	-9.3%	12,066,000	13,305,000	12,105,000	12,356,000	10,028,000	10,912,000	9,603,000	12,081,000	8,038,000	10,209,000	7,204,000	16,261,000
EBITDA Margin	39.2%	-2.92	-4.80	-4.09	-2.13	-2.31	-	-	-	-	-	-	-
Interest Expenses	-12.2%	868,000	989,000	858,000	684,000	699,000	633,000	544,000	316,000	-	-	-	-
Income Taxes	-	-	-	-	-	-	-5,000	-	1,000	54,000	-341,000	29,000	313,000
EBT Margin	39.1%	-3.02	-4.95	-4.32	-2.24	-2.41	-0.41	-0.33	-0.28	-0.24	-	-	-
Net Income	14.7%	-35,731,000	-41,902,000	-39,148,000	-23,419,000	-13,599,000	-22,511,000	-5,743,000	-20,238,000	-14,851,000	-15,697,000	6,345,000	10,376,000
Net Income Margin	33.6%	-3.29	-4.95	-7.49	-2.35	-2.41	-1.88	-1.36	-0.90	-0.24	-	-	-
Free Cashflow	3.5%	-37,963,000	-39,335,000	-32,737,000	-22,310,000	-11,001,000	-18,707,000	-4,381,000	-15,447,000	-12,395,000	6,991,000	20,535,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	31.6%	349	265	268	189	211	228	236	253	181	179	190	203	194	172	92.00	58.00
Current Assets	33.0%	341	256	259	183	209	225	234	250	179	176	187	201	191	171	89.00	58.00
Cash Equivalents	-13.9%	194	225	227	107	66.00	72.00	169	245	175	171	184	177	156	168	86.00	58.00
Inventory	29.9%	4.00	3.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-8.9%	1.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	1.00	1.00	1.00	0.00
Liabilities	8.1%	74.00	69.00	55.00	41.00	38.00	35.00	34.00	31.00	32.00	12.00	11.00	11.00	11.00	6.00	7.00	1.00
Current Liabilities	15.1%	43.00	37.00	23.00	15.00	13.00	15.00	14.00	12.00	13.00	11.00	10.00	10.00	10.00	5.00	6.00	1.00
Long Term Debt	0.4%	30.00	30.00	30.00	25.00	25.00	19.00	19.00	19.00	19.00	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	30.00	30.00	25.00	25.00	19.00	19.00	19.00	19.00	-	-	-	-	-	-	-
Shareholder's Equity	39.7%	275	197	214	148	173	193	203	222	149	167	179	192	183	166	-	-
Retained Earnings	-14.6%	-280	-244	-202	-163	-132	-108	-95.16	-72.65	-66.91	-46.67	-31.80	-16.12	-22.47	-32.80	-21.38	-6.03
Additional Paid-In Capital	25.8%	556	442	416	311	306	302	298	294	216	213	211	209	206	199	4.00	0.00
Shares Outstanding	10.4%	38.00	34.00	33.00	27.00	27.00	27.00	24.00	23.00	21.00	21.00	21.00	20.00	-	-	-	-
Float	-	-	-	-	460	-	-	-	181	-	-	-	484	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	3.9%	-37,789	-39,335	-32,362	-23,826	-21,970	-10,874	-18,611	-4,259	-15,286	-12,121	7,112	20,551	-11,794	-10,013	-6,572	-2,557	-1,996	-	-
Share Based Compensation	0.7%	5,519	5,482	5,250	5,192	3,906	3,671	3,583	3,532	2,674	2,179	2,119	2,794	1,363	438	224	173	4.00	-	-
Cashflow From Investing	-672.7%	-102,224	17,850	47,368	64,092	11,294	-87,219	-57,127	-122	-161	-274	-121	-16.00	-175	50.00	-135	-335	-36.00	-	-
Cashflow From Financing	450.5%	108,771	19,760	104,893	510	5,013	264	-136	74,734	19,125	-74.00	75.00	1.00	19.00	91,763	39,901	134	-27.00	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TARS Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 27,614	$ 2,500
Operating expenses:
Research and development	12,066	12,356
Selling, general and administrative	51,578	15,096
Total operating expenses	65,298	27,452
Loss from operations before other income (expense)	(37,684)	(24,952)
Other income (expense):
Interest income	3,117	2,293
Interest expense	(983)	(684)
Other income, net	605	6
Unrealized loss on equity investments	(585)	(65)
Change in fair value of equity warrants issued by licensee	(201)	(17)
Total other income, net	1,953	1,533
Net (loss) income	(35,731)	(23,419)
Other comprehensive loss:
Unrealized (loss) gain on marketable securities and cash equivalents	(61)	4
Comprehensive loss	$ (35,792)	$ (23,415)
Earnings Per Share [Abstract]
Net loss per share, basic (usd per share)	$ (1.01)	$ (0.88)
Net loss per share, diluted (usd per share)	$ (1.01)	$ (0.88)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Weighted-average shares outstanding, basic (shares)	35,300,655	26,742,023
Weighted-average shares outstanding, diluted (shares)	35,300,655	26,742,023
Product
Revenues:
Total revenues	$ 24,720	$ 0
Operating expenses:
Cost of sales	1,654	0
License fees and Collaboration
Revenues:
Total revenues	$ 2,894	$ 2,500

TARS Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 193,705	$ 224,947
Marketable securities	104,819	2,495
Accounts receivable, net	29,885	16,621
Inventory	4,036	3,107
Other receivables	1,476	1,093
Prepaid expenses	6,803	7,868
Total current assets	340,724	256,131
Property and equipment, net	1,338	1,468
Intangible assets, net	3,767	3,867
Operating lease right-of-use assets	2,132	1,880
Long-term investments	0	631
Other assets	1,317	1,514
Total assets	349,278	265,491
Current liabilities:
Accounts payable and other accrued liabilities	36,570	23,691
Accrued payroll and benefits	5,958	13,245
Total current liabilities	42,528	36,936
Term loan, net	29,933	29,819
Other long-term liabilities	1,606	1,748
Total liabilities	74,067	68,503
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 authorized; no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 200,000,000 shares authorized; 37,749,468 shares issued and outstanding at March 31, 2024 (unaudited); 34,211,190 shares issued and outstanding at December 31, 2023	6	5
Additional paid-in capital	555,655	441,641
Accumulated other comprehensive loss	(63)	(2)
Accumulated deficit	(280,387)	(244,656)
Total stockholders’ equity	275,211	196,988
Total liabilities and stockholders’ equity	$ 349,278	$ 265,491

About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

CEO	Dr. Bobak R. Azamian M.D.
WEBSITE	tarsusrx.com
INDUSTRY	Biotechnology
EMPLOYEES	87

Tarsus Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Tarsus Pharmaceuticals Inc? What does TARS stand for in stocks?

TARS is the stock ticker symbol of Tarsus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tarsus Pharmaceuticals Inc (TARS)?

As of Mon May 13 2024, market cap of Tarsus Pharmaceuticals Inc is 1.45 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TARS stock?

You can check TARS's fair value in chart for subscribers.

What is the fair value of TARS stock?

You can check TARS's fair value in chart for subscribers. The fair value of Tarsus Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tarsus Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TARS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tarsus Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether TARS is over valued or under valued. Whether Tarsus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Tarsus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TARS.

What is Tarsus Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, TARS's PE ratio (Price to Earnings) is -9.8 and Price to Sales (PS) ratio is 32.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TARS PE ratio will change depending on the future growth rate expectations of investors.